Last reviewed · How we verify
BF-200 ALA 3%
BF-200 ALA 3% is a topical cream used to treat actinic keratosis.
BF-200 ALA 3% is a topical cream used to treat actinic keratosis. Used for Actinic keratosis.
At a glance
| Generic name | BF-200 ALA 3% |
|---|---|
| Sponsor | Biofrontera Bioscience GmbH |
| Drug class | Topical photodynamic therapy agent |
| Target | 5-aminolevulinic acid (ALA) synthase |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the enzyme 5-aminolevulinic acid (ALA) synthase, which is involved in the production of porphyrins. The porphyrins then accumulate in the skin cells and cause cell death, leading to the removal of the affected cells.
Approved indications
- Actinic keratosis
Common side effects
- Skin irritation
- Phototoxicity
- Pruritus
Key clinical trials
- Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions (PHASE2)
- Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT) (NA)
- Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA） (PHASE3)
- 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma (EARLY_PHASE1)
- Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma (EARLY_PHASE1)
- Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp (PHASE3)
- Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas (PHASE1)
- Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BF-200 ALA 3% CI brief — competitive landscape report
- BF-200 ALA 3% updates RSS · CI watch RSS
- Biofrontera Bioscience GmbH portfolio CI